Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00671658 · ClinicalTrials.gov registry record · Phase 2
Modified Hyper-CVAD (Cyclophosphamide, Vincristine, Adriamycin, and Dexamethasone) Program for Acute Lymphoblastic Leukemia
A Phase 2 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 220
- Enrollment target
NCT00671658: Completed Phase 2 study, sponsored by M.D. Anderson Cancer Center.
NCT00671658 is a Phase 2 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 220 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00671658, a Phase 2 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 220 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to learn if intensive chemotherapy (with monoclonal antibody therapy in some patients) given for 8 courses over 5 to 6 months followed by monthly maintenance chemotherapy for 2 ½ years can improve or cure acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma.
Interventions
- DRUG Doxorubicin
- DRUG Rituximab
- DRUG Dexamethasone
- DRUG Vincristine
- DRUG Cyclophosphamide (CTX)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 220 participants |
| Start Date | 2002-11 |
| Est. Completion | 2013-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00671658
The ClinicalTrials.gov registry entry for NCT00671658 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 220 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Doxorubicin is the first listed.
NCT00671658 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00671658 about?
NCT00671658 is a clinical study titled "Modified Hyper-CVAD (Cyclophosphamide, Vincristine, Adriamycin, and Dexamethasone) Program for Acute Lymphoblastic Leukemia". The goal of this clinical research study is to learn if intensive chemotherapy (with monoclonal antibody therapy in some patients) given for 8 courses over 5 to 6 months followed by monthly maintenance chemotherapy for 2 ½ years can improve or cure acute lymphoblastic leukemia (ALL) or lymphoblastic...
What is the current status of trial NCT00671658?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 220 participants. The study started on 2002-11. Estimated completion is 2013-07.
What interventions are being tested in trial NCT00671658?
The interventions under investigation include: Doxorubicin (DRUG), Rituximab (DRUG), Dexamethasone (DRUG), Vincristine (DRUG), Cyclophosphamide (CTX) (DRUG).
Who is sponsoring clinical trial NCT00671658?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.